Fate Therapeutics (FATE) Tops Q3 EPS by 6c

Fate Therapeutics (NASDAQ: FATE) reported Q3 EPS of ($0.24), $0.06 better than the analyst estimate of ($0.30). Revenue for the quarter came in at $1 million versus the consensus estimate of $430 thousand.

For earnings history and earnings-related data on Fate Therapeutics (FATE) click here.

You May Also Be Interested In

• Ennis (EBF) Reports In-Line Q1 EPS
• CRH agrees to buy Arcosa in $8.5B all-cash deal
• Syensqo SA (SYENS:BB) PT Raised to EUR74 at Deutsche Bank